![Fiona McLaughlin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fiona McLaughlin
Chief Tech/Sci/R&D Officer at
THALIA THERAPEUTICS PLC
Profile
Fiona McLaughlin is currently Non-Executive Director at Hox Therapeutics Ltd. since 2023 and Head-Research & Development at Thalia Therapeutics Plc starting in 2025.
Former roles include Chief Scientific Officer-Therapeutics Division at Avacta Group Plc from 2021 to 2024, Vice President-New Opportunities at Algeta ASA from 2011 to 2014, Vice President-Translational Research at Sarossa Capital Ltd. from 2007 to 2010, and Director-Pre Clinical Development at BTG Ltd. from 2003 to 2006.
Education includes undergraduate studies at the University of Glasgow and a doctorate from the University of Cambridge.
Fiona McLaughlin active positions
| Companies | Position | Start |
|---|---|---|
| THALIA THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 27/05/2025 |
Hox Therapeutics Ltd.
 Hox Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for cancer diseases based on the role of HOX genes | Director/Board Member | 01/12/2023 |
Former positions of Fiona McLaughlin
| Companies | Position | End |
|---|---|---|
| AVACTA GROUP PLC | Chief Tech/Sci/R&D Officer | 01/06/2024 |
| ALGETA ASA | Corporate Officer/Principal | 01/04/2014 |
Sarossa Capital Ltd.
 Sarossa Capital Ltd. Financial ConglomeratesFinance Provides investment services | Corporate Officer/Principal | 01/07/2010 |
| BTG | Chief Tech/Sci/R&D Officer | 01/01/2006 |
Training of Fiona McLaughlin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
42
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies drugs used in the treatment of neurological disorders | Health Technology |
Sarossa Capital Ltd.
Sarossa Capital Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
University of Glasgow
 University of Glasgow Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Engages in the development of products for the treatment of cancer | Health Technology |
N4 Pharma Plc
 N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Hox Therapeutics Ltd.
Hox Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for cancer diseases based on the role of HOX genes | Health Technology |
- Stock Market
- Insiders
- Fiona McLaughlin
